细胞毒性T细胞
癌症研究
免疫疗法
生物
T细胞
移植
免疫学
作者
Siler H Panowski,Surabhi Srinivasan,Nguyen Tan,Silvia K. Tacheva-Grigorova,Bryan Smith,Yvonne Mak,Hongxiu Ning,Jonathan Villanueva,Dinali Wijewarnasuriya,Shanshan Lang,Zea Melton,Adit Ghosh,Mathilde Dusseaux,Roman Galetto,Jonathan R. Heyen,Tao Sai,Thomas Van Blarcom,Javier Chaparro-Riggers,Barbra Sasu
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2022-03-16
标识
DOI:10.1158/0008-5472.can-21-2931
摘要
Abstract CD70 is highly expressed in renal cell carcinoma (RCC), with limited expression in normal tissue, making it an attractive CAR T target for an immunogenic solid tumor indication. Here we generated and characterized a panel of anti-CD70 scFv-based CAR T cells. Despite the expression of CD70 on T cells, production of CAR T from a subset of scFvs with potent in vitro activity was achieved. Expression of CD70 CARs masked CD70 detection in cis and provide protection from CD70 CAR T-mediated fratricide. Two distinct classes of CAR T cells were identified with differing memory phenotype, activation status, and cytotoxic activity. Epitope mapping revealed that the two classes of CARs bind unique regions of CD70. CD70 CAR T cells displayed robust antitumor activity against RCC cell lines and patient-derived xenograft mouse models. Tissue cross-reactivity studies identified membrane staining in lymphocytes, thus matching the known expression pattern of CD70. In a cynomolgus monkey CD3-CD70 bispecific toxicity study, expected findings related to T cell activation and elimination of CD70-expressing cells were observed, including cytokine release and loss of cellularity in lymphoid tissues. Lastly, highly functional CD70 allogeneic CAR T cells were produced at large scale through elimination of the T cell receptor by TALEN-based gene editing. Taken together, these efficacy and safety data support the evaluation of CD70 CAR T cells for the treatment of RCC and has led to the advancement of an allogeneic CD70 CAR T candidate into phase I clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI